GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma (GINAKIT2)
GD2 Specific Chimeric Antigen Receptor (CAR) and Interleukin-15 Expressing Autologous Natural Killer T-cells to Treat Children With Neuroblastoma
Researchers at Texas Children’s Hospital seek children with neuroblastoma to trial an investigatory treatment that gene-modifies their own immune natural killer T cells (NKT) to add 3 genes:
- A gene to produce molecules on their surface that recognize neuroblastoma cells
- A gene to make the NKT cells live longer
- A gene to produce Interleukin 15 (IL-15) which stimulates immune response to tumors
After leukapheresis to collect the T-cells, they are gene-modified in the lab, then returned to the patient following chemotherapy. Follow up may continue for up to 15 years.
- Be 1 to 21 years of age
- Have relapsed or refractory high risk neuroblastoma
- Life expectancy of at least 12 weeks
- Weigh greater than 12kg
THE STUDY INVOLVES:
- Screening to confirm acceptance to the study.
- Leukapheresis to isolate T-cells which are then modified in the lab.
- Chemotherapy for 3 days.
- The gene-modified T cells will be administered through an IV line following a day of rest.
- Follow up will be required for 15 years.
LOCATIONS & CONTACTS:
The study site is at Texas Children’s Hospital in Houston, TX Map.
Andras Heczey, MD | 832-824-4233 | [email protected]
Josalind Randall | 832-824-6835 | [email protected]
Baylor College of Medicine
Center for Cell and Gene Therapy, Baylor College of Medicine
Texas Children’s Hospital
Or go online: